Please refer to ClinicalTrials.gov : NCT03954041
Phase 2
Terminated
- Conditions
- Brain Contusion
- Registration Number
- JPRN-jRCT2080224849
- Lead Sponsor
- Biogen Japan Ltd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- terminated
- Sex
- All
- Target Recruitment
- 160
Inclusion Criteria
Please refer to ClinicalTrials.gov : NCT03954041
Exclusion Criteria
Please refer to ClinicalTrials.gov : NCT03954041
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms does Biogen Japan's Phase II Brain Contusion trial investigate, such as neuroinflammation or cell survival pathways?
How does the intervention in JPRN-jRCT2080224849 compare to standard-of-care treatments like corticosteroids for traumatic brain injury outcomes?
Which biomarkers are used in JPRN-jRCT2080224849 to predict response to the Brain Contusion treatment?
What are the potential adverse events of Biogen Japan's experimental therapy for Brain Contusion in Phase II trials and their management strategies?
Are there any combination therapies or competitor drugs being tested for Brain Contusion alongside Biogen Japan's intervention in Phase II?